

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Porcilis Ery suspension for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml dose contains:

Active substance:

Inactivated lysed antigen concentrate of *Erysipelothrix rhusiopathiae* strain M2 (serotype 2): $\geq 1\text{ppd}^*$

*ppd = pig protective dose, determined by reference to a standard vaccine batch.

Adjuvant:

dl- α -tocopherol acetate: 150 mg

Excipients:

Qualitative composition of excipients and other constituents
Sodium chloride
Tris (hydrocymethyl) aminomethane
Polysorbate 80
Simethicone
Hydrochloric acid
Water for injection

Homogenous white to nearly white suspension after shaking.

3. CLINICAL INFORMATION

3.1 Target species

Pigs (sows, gilts, boars and growing pigs).

3.2 Indications for use for each target species

For active immunisation of healthy pigs to reduce clinical signs and lesions caused by Erysipelas disease. To maintain protection, animals should be re-vaccinated at no more than six monthly intervals.

Duration of immunity: 6 months.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. If spilled on the skin, wash with soap and water. If ingested, drink water. If symptoms develop, seek medical advice.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Pigs (sows, gilts, boars and growing pigs):

Very common (>1 animal / 10 animals treated):	Elevated temperature ¹ . Injection site swelling ² .
Common (1 to 10 animals / 100 animals treated):	Reluctant to move ³ .
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction.

¹ Transient increases in body temperature (0.5 °C) within 24 hours.

² Mild and transient (less than 5cm in diameter, normally within 3 days).

³ Transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Stress should be avoided when vaccinating animals, particularly during later stages of pregnancy.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Deep intramuscular use.

Administer one dose of 2 ml per pig by deep intramuscular injection behind the ear.

Ensure the vaccination equipment is clean and sterile before use. Avoid the introduction of contamination by multiple broaching.

Allow vaccine to reach room temperature (15 °C - 25 °C) before use.

Shake well before and during use.

Vaccination programmes

Young growing pigs:

Pigs should be at least 6 weeks of age. A course of two doses given 4 weeks apart, is recommended.

Breeding stock:

Primary vaccination: for the induction of protection against erysipelas, an initial course of two doses, given 4 weeks apart, is recommended. When protection against parvovirus is also required, this can be achieved with Porcilis Ery given either 4 weeks before, or 4 weeks after, administration of the Porcilis Ery + Parvo. Boars, sows and gilts should be vaccinated against *E. rhusiopathiae* at least 2 weeks before mating.

Booster vaccination: Sows and boars should be vaccinated (a single dose of 2 ml) against erysipelas at six monthly intervals. For sows this may be during each lactation period, at weaning or during pregnancy (avoiding the last two weeks).

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Reactions observed after administration of a double dose are not different from those observed after administration of a single dose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION**4.1 ATCvet code: QI09AB03.**

The active ingredient is an inactivated antigen of *Erysipelothrix rhusiopathiae* which induces active immunity in vaccinated animals. The antigen is incorporated in an aqueous tocopherol based adjuvant in order to enhance a prolonged stimulation of immunity.

5. PHARMACEUTICAL PARTICULARS**5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 24 months.
Shelf life after first opening the immediate packaging: 10 hours.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use.

5.4 Nature and composition of immediate packaging

PET-vial closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.

Package sizes:

1 vial of 20 ml (10 doses), 50 ml (25 doses), 100 ml (50 doses) or 250 ml (125 doses) packed in a cardboard box.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet Ireland Limited

7. MARKETING AUTHORISATION NUMBER(S)

VPA 10996/096/001

8. DATE OF FIRST AUTHORISATION

10/04/2001

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

27/06/2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).